Hepatic encephalopathy · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes hepatic encephalopathy assessed based on neurocognitive manifestations compared with lactulose (very low certainty).
1 finding from 1 review
Serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes serious adverse events assessed using ICH‐GCP compared with lactulose (very low certainty).
1 finding from 1 review
Quality of life assessed using questionnaires · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with Child‐Pugh stage A or B cirrhosis
Exercise showed no clear difference in all‐cause mortality compared with no exercise (moderate certainty).
1 finding from 1 review
Serious adverse events · people with Child‐Pugh stage A or B cirrhosis
Exercise showed no clear difference in serious adverse events compared with no exercise (low certainty).
1 finding from 1 review
Health‐related quality of life (HRQoL) · people with Child‐Pugh stage A or B cirrhosis
1 finding from 1 review
Anthropometric measurements: mid‐arm circumference (cm) · people with Child‐Pugh stage A or B cirrhosis
1 finding from 1 review
Anthropometric measurements: mid‐thigh circumference (cm) · people with Child‐Pugh stage A or B cirrhosis
1 finding from 1 review
Physical fitness: peak exercise oxygen uptake (mL/kg/minute) · people with Child‐Pugh stage A or B cirrhosis
1 finding from 1 review
Physical fitness · people with Child‐Pugh stage A or B cirrhosis
1 finding from 1 review
Mortality Clinically · people with hepatic encephalopathy
Branched‐chain amino acids (BCAA) showed no clear difference in mortality Clinically compared with control (moderate certainty).
1 finding from 1 review
Hepatic encephalopathy · people with hepatic encephalopathy
Branched‐chain amino acids (BCAA) leads to lower hepatic encephalopathy Psychometric and clinical assessments compared with control (high certainty).
1 finding from 1 review
Nausea and diarrhoea Clinically · people with hepatic encephalopathy
Branched‐chain amino acids (BCAA) showed no clear difference in nausea and diarrhoea Clinically compared with control (low certainty).
1 finding from 1 review
Albumin Laboratory assessment · people with hepatic encephalopathy
1 finding from 1 review
Nitrogen balance Laboratory assessment · people with hepatic encephalopathy
1 finding from 1 review
All‐cause mortality · people with hepatic encephalopathy
Flumazenil showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Hepatic encephalopathy · people with hepatic encephalopathy
Flumazenil may leads to lower hepatic encephalopathy compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with hepatic encephalopathy
1 finding from 1 review
All‐cause mortality · people with hepatorenal syndrome
Terlipressin may leads to lower mortality compared with placebo or no intervention (low certainty).
1 finding from 1 review
Hepatorenal syndrome · people with hepatorenal syndrome
Terlipressin may leads to lower hepatorenal syndrome compared with placebo or no intervention (low certainty).
1 finding from 1 review